Patents by Inventor Hongbiao Liao

Hongbiao Liao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11911475
    Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Grant
    Filed: June 24, 2022
    Date of Patent: February 27, 2024
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Matthew G. Stanton, Brian W. Budzik, Gregory L. Beutner, Hongbiao Liao
  • Publication number: 20230000989
    Abstract: The instant invention provides for novel catiomc lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Application
    Filed: June 24, 2022
    Publication date: January 5, 2023
    Applicant: SIRNA THERAPEUTICS, INC.
    Inventors: Matthew G. Stanton, Brian W. Budzik, Gregory L. Beutner, Hongbiao Liao
  • Patent number: 11413348
    Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: August 16, 2022
    Assignee: SIRNA THEREPEUTICS, INC.
    Inventors: Matthew G. Stanton, Brian W. Budzik, Gregory L. Beutner, Hongbiao Liao
  • Publication number: 20200222540
    Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Application
    Filed: January 13, 2020
    Publication date: July 16, 2020
    Applicant: SIRNA THERAPEUTICS, INC.
    Inventors: Matthew G. Stanton, Brian W. Budzik, Gregory L. Beutner, Hongbiao Liao
  • Patent number: 10576155
    Abstract: The instant invention provides for novel catiome lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: March 3, 2020
    Assignee: SIRNA THEREAPEUTICS, INC.
    Inventors: Matthew G. Stanton, Brian W. Budzik, Gregory L. Beutner, Hongbiao Liao
  • Patent number: 10214742
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; and optionally, 4) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: February 26, 2019
    Assignee: Sima Therapeutics, Inc.
    Inventors: David Tellers, Steven Colletti, Vadim Dudkin, Norihiro Ikemoto, Hongbiao Liao, Craig Parish, Tao Pei, Anthony Shaw, Quang Truong, Lijun Wang, Yu Yuan, Man Zhu
  • Publication number: 20180000939
    Abstract: The instant invention provides for novel catiome lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Application
    Filed: May 10, 2017
    Publication date: January 4, 2018
    Applicant: SIRNA THERAPEUTICS, INC.
    Inventors: Matthew G. Stanton, Brian W. Budzik, Gregory L. Beutner, Hongbiao Liao
  • Publication number: 20170233731
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; and optionally, 4) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Application
    Filed: November 29, 2016
    Publication date: August 17, 2017
    Inventors: David TELLERS, Steven COLLETTI, Vadim DUDKIN, Norihiro IKEMOTO, Hongbiao LIAO, Craig PARISH, Tao PEI, Anthony SHAW, Quang TRUONG, Lijun WANG, Yu YUAN, Man ZHU
  • Patent number: 9669097
    Abstract: The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Grant
    Filed: September 20, 2011
    Date of Patent: June 6, 2017
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Matthew G. Stanton, Brian W. Budzik, Gregory L. Beutner, Hongbiao Liao
  • Patent number: 9540639
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; and optionally, 4) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: January 10, 2017
    Assignee: Sirna Therapeutics, Inc.
    Inventors: David Tellers, Steven Colletti, Vadim Dudkin, Norihiro Ikemoto, Hongbiao Liao, Craig Parish, Tao Pei, Anthony Shaw, Quang Truong, Lijun Wang, Yu Yuan, Man Zhu
  • Publication number: 20150203843
    Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; and optionally, 4) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.
    Type: Application
    Filed: May 1, 2013
    Publication date: July 23, 2015
    Inventors: David Tellers, Steven Colletti, Vadim Dudkin, Norihiro Ikemoto, Hongbiao Liao, Craig Parish, Tao Pei, Anthony Shaw, Quang Truong, Lijun Wang, Yu Yuan, Man Zhu
  • Patent number: 8680294
    Abstract: Processes useful for the preparation of a Compound of Formula I: Formula (I). Intermediates useful for the preparation of the compound of Formula I, and processes useful for preparing said intermediates are disclosed.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: March 25, 2014
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John Traverse, William M. Leong, Steven P. Miller, Jennifer Albaneze-Walker, Thomas J. Hunter, Lijun Wang, Hongbiao Liao, Ashok Arasappan, Scott T. Trzaska, Randi M. Smith, Azzeddine Lekhal, Stephane L. Bogen, Jianshe Kong, Frank Bennett, F. George Njoroge, Marc Poirier, Shen-Chun Kuo, Yonggang Chen, Kenneth S. Matthews, Patrice Demonchaux, Amadeo Ferreira
  • Publication number: 20130178541
    Abstract: The instant invention provides for novel catiomc lipids that can be used in combination with other lipid components such as cholesterol and PEG-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. The present invention employs low molecular weight cationic lipids with one short lipid chain to enhance the efficiency and tolerability of in vivo delivery of siRNA.
    Type: Application
    Filed: September 20, 2011
    Publication date: July 11, 2013
    Inventors: Matthew G. Stanton, Brian W. Budzik, Gregory L. Beutner, Hongbiao Liao
  • Publication number: 20120178942
    Abstract: Processes useful for the preparation of a Compound of Formula I: Formula (I). Intermediates useful for the preparation of the compound of Formula I, and processes useful for preparing said intermediates are disclosed.
    Type: Application
    Filed: July 27, 2010
    Publication date: July 12, 2012
    Inventors: John Traverse, William M. Leong, Steven P. Miller, Jennifer Albaneze-Walker, Thomas J. Hunter, Lijun Wang, Hongbiao Liao, Ashok Arasappan, Scott T. Trzaska, Randi M. Smith, Azzeddine Lekhal, Stephane L. Bogen, Jianshe Kong, Frank Bennett, F. George Njoroge, Marc Poirier, Shen-Chun Kuo, Yonggang Chen, Kenneth S. Matthews, Patrice Demonchaux, Amadeo Ferreira
  • Publication number: 20120065397
    Abstract: The present invention discloses a novel process to prepare ketone amides, which are useful intermediates for the preparation of antagonists of CCR5 receptor and therefore useful for the treatment of HIV virus infected mammals. It specifically discloses a novel process to synthesize 1-(2,4-dimethylpyrimidine-5-carbonyl)-4-piperidone, 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4-piperidone and related compounds. A salient feature of the invention is the use of a three-phase reaction medium with an organic phase and a buffer salt slurry.
    Type: Application
    Filed: November 23, 2011
    Publication date: March 15, 2012
    Applicant: Scherimg Corporation
    Inventors: Shen-Chun KUO, David Jieh-Shyh TSAI, Hongbiao LIAO
  • Publication number: 20100249411
    Abstract: In an illustrative embodiment, the present invention describes the synthesis of the following compound and similar compounds, in high stereochemical purity by a novel stereoselective alkylation process:
    Type: Application
    Filed: March 29, 2010
    Publication date: September 30, 2010
    Inventors: Wenxue Wu, Hongbiao Liao, David J.S. Tsai, David R. Andrews, Dinesh Gala, Gary M. Lee, Martin Lawrence Schwartz, Timothy L. McAllister, Xiaoyong Fu, Donal Maloney, Tiruvettipuram K. Thiruvengadam, Chou-Hang Tann
  • Patent number: 7759487
    Abstract: The present invention discloses a novel process to prepare ketone amides, which are useful intermediates for the preparation of antagonists of CCR5 receptor and therefore useful for the treatment of HIV virus infected mammals. It specifically discloses a novel process to synthesize 1-(2,4-dimethylpyrimidine-5-carbonyl)-4-piperidone, 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4-piperidone and related compounds. A salient feature of the invention is the use of a three-phase reaction medium with an organic phase and a buffer salt slurry.
    Type: Grant
    Filed: January 5, 2006
    Date of Patent: July 20, 2010
    Assignee: Schering Corporation
    Inventors: Shen-Chun Kuo, David Jieh-Shyh Tsai, Hongbiao Liao
  • Patent number: 7745626
    Abstract: In an illustrative embodiment, the present invention describes the synthesis of the following compound and similar compounds, in high stereochemical purity by a novel stereoselective alkylation process:
    Type: Grant
    Filed: March 25, 2005
    Date of Patent: June 29, 2010
    Assignee: Schering Corporation
    Inventors: Wenxue Wu, Hongbiao Liao, David J. Tsai, David R. Andrews, Dinesh Gala, Gary M. Lee, Martin Lawrence Schwartz, Timothy L. McAllister, Xiaoyong Fu, Donal Maloney, Tiruvettipuram K. Thiruvengadam, Chou-Hang Tann
  • Publication number: 20100029939
    Abstract: The present invention discloses a novel process to prepare ketone amides, which are useful intermediates for the preparation of antagonists of CCR5 receptor and therefore useful for the treatment of HIV virus infected mammals. It specifically discloses a novel process to synthesize 1-(2,4-dimethylpyrimidine-5-carbonyl)-4-piperidone, 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4-piperidone and related compounds. A salient feature of the invention is the use of a three-phase reaction medium with an organic phase and a buffer salt slurry.
    Type: Application
    Filed: September 22, 2009
    Publication date: February 4, 2010
    Inventors: SHEN-CHUN KUO, David Jieh-Shyh Tsai, Hongbiao Liao
  • Patent number: 7534884
    Abstract: In one embodiment, the present invention discloses a process to directly prepare an unequal ratio of rotamers of an acid salt from a basic compound, by creative choice of a solvent medium. The process is particularly useful in preparing specific rotamers of pharmaceutically useful salts in desired preponderance.
    Type: Grant
    Filed: March 30, 2005
    Date of Patent: May 19, 2009
    Assignee: Schering Corporation
    Inventors: Dinesh Gala, Andrew J. Goodman, Gary Lee, Hongbiao Liao, Martin L. Schwartz, Suhan Tang, David J. S. Tsai, Wenxue Wu